Related references
Note: Only part of the references are listed.Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
Piergiorgio Pettazzoni et al.
CANCER RESEARCH (2015)
mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer
Feng Wei et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2
Heloisa P. Soares et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer
Sabiha Kazim et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
T. Golan et al.
BRITISH JOURNAL OF CANCER (2014)
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Andrew D. Rhim et al.
CANCER CELL (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers
Andreas M. Heilmann et al.
CANCER RESEARCH (2014)
Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Edward J. Kim et al.
CLINICAL CANCER RESEARCH (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
Targeting mTOR dependency in pancreatic cancer
Douglas C. Morran et al.
GUT (2014)
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines
Patricia Izetti et al.
INVESTIGATIONAL NEW DRUGS (2014)
ARID1B is a specific vulnerability in ARID1A-mutant cancers
Katherine C. Helming et al.
NATURE MEDICINE (2014)
Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression
Pauli Puolakkainen et al.
MEDICAL ONCOLOGY (2014)
Notch pathway activation is associated with pancreatic cancer treatment failure
Jin Young Lee et al.
PANCREATOLOGY (2014)
Failure Patterns in Resected Pancreas Adenocarcinoma Lack of Predicted Benefit to SMAD4 Expression
Jordan M. Winter et al.
ANNALS OF SURGERY (2013)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Discontinued drugs in 2012: oncology drugs
Robert Williams
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer
Jiujie Cui et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Somatic Mutations in the Chromatin Remodeling Gene ARID1A Occur in Several Tumor Types
Sian Jones et al.
HUMAN MUTATION (2012)
Cdk4/6 Inhibition Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
Fang Liu et al.
MOLECULAR CANCER THERAPEUTICS (2012)
RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis
Min Yu et al.
NATURE (2012)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin et al.
NATURE (2012)
Histone methylation: a dynamic mark in health, disease and inheritance
Eric L. Greer et al.
NATURE REVIEWS GENETICS (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors
Austin Gurney et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Stromal Cell-Derived Factor 1α Mediates Resistance to mTOR-Directed Therapy in Pancreatic Cancer
Colin D. Weekes et al.
NEOPLASIA (2012)
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Peter Bouwman et al.
NATURE REVIEWS CANCER (2012)
被撤回的出版物: Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells (Retracted article. See vol. 423, pg. 153, 2018)
Bin Bao et al.
CANCER LETTERS (2011)
ARID1A, a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers
Bin Guan et al.
CANCER RESEARCH (2011)
MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
N. V. Rajeshkumar et al.
CLINICAL CANCER RESEARCH (2011)
A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.
C. M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression
Christopher H. Crane et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Novel TGF-β Antagonist Inhibits Tumor Growth and Angiogenesis by Inducing IL-2 Receptor-Driven STAT1 Activation
Claudia Penafuerte et al.
JOURNAL OF IMMUNOLOGY (2011)
Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis
Alyssa L. Kennedy et al.
MOLECULAR CELL (2011)
Targeting the missing links for cancer therapy
Kornelia Polyak et al.
NATURE MEDICINE (2011)
Pancreatic Ductal Adenocarcinoma Derived From IPMN and Pancreatic Ductal Adenocarcinoma Concomitant With IPMN
Koji Yamaguchi et al.
PANCREAS (2011)
Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development
Jian Wu et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Novel roles for Slits and netrins: axon guidance cues as anticancer targets?
Patrick Mehlen et al.
NATURE REVIEWS CANCER (2011)
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
Milind M. Javle et al.
BMC CANCER (2010)
PTEN Loss Accelerates KrasG12D-Induced Pancreatic Cancer Development
Reginald Hill et al.
CANCER RESEARCH (2010)
Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy
A. S. Azmi et al.
CURRENT CANCER DRUG TARGETS (2010)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The activating mutation R201C in GNAS promotes intestinal tumourigenesis in ApcMin/+ mice through activation of Wnt and ERK1/2 MAPK pathways
C. H. Wilson et al.
ONCOGENE (2010)
Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway
Zhiwei Wang et al.
CANCER RESEARCH (2009)
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Amanda Blackford et al.
CLINICAL CANCER RESEARCH (2009)
Hedgehog Target Genes: Mechanisms of Carcinogenesis Induced by Aberrant Hedgehog Signaling Activation
Y. Katoh et al.
CURRENT MOLECULAR MEDICINE (2009)
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
Bryan T. MacDonald et al.
DEVELOPMENTAL CELL (2009)
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
Christine A. Iacobuzio-Donahue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Suppression of induced pluripotent stem cell generation by the p53-p21 pathway
Hyenjong Hong et al.
NATURE (2009)
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Chen Zhao et al.
NATURE (2009)
Brief Report: Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449.
Charles M. Rudin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4
Jeongkyung Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Wnt signaling promotes reprogramming of somatic cells to pluripotency
Alexander Marson et al.
CELL STEM CELL (2008)
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
Jennifer M. Bailey et al.
CLINICAL CANCER RESEARCH (2008)
Hedgehog Signaling in Development and Cancer
Jin Jiang et al.
DEVELOPMENTAL CELL (2008)
Pancreatic cancer stem cells
Cheong J. Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The ADAM metalloproteinases
Dylan R. Edwards et al.
MOLECULAR ASPECTS OF MEDICINE (2008)
Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia
De La O. Jean-Paul et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, notch, and bone morphogenic proteins
Jennifer M. Bailey et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer
N. Valkovskaya et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2007)
Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding
Maria Gomez-Gaviro et al.
JOURNAL OF IMMUNOLOGY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Snail is required for transforming growth factor-β-induced epithelial-mesenchymal transition by activating PI3 kinase/Akt signal pathway
Hee Jun Cho et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Identification of pancreatic cancer stem cells
Chenwei Li et al.
CANCER RESEARCH (2007)
Chromatin remodeling and cancer, part II: ATP-dependent chromatin remodeling
Gang G. Wang et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Cancer epigenomics: DNA methylomes and histone-modification maps
Manel Esteller
NATURE REVIEWS GENETICS (2007)
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Jirina Bartkova et al.
NATURE (2006)
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas
Frank Schoenleben et al.
CLINICAL CANCER RESEARCH (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer
D Ito et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Aberrant Wnt/β-catenin signaling in pancreatic adenocarcinoma
Gang Zeng et al.
NEOPLASIA (2006)
被撤回的出版物: Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear Factor-κB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. (Retracted article. See vol. 78, pg. 5476, 2018)
ZW Wang et al.
CANCER RESEARCH (2006)
Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers
H Taniguchi et al.
ONCOGENE (2005)
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas
BZ Stanger et al.
CANCER CELL (2005)
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
Y Samuels et al.
CANCER CELL (2005)
β-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: Relationships with carcinogenesis and metastasis
Yu-Jun Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Wnt signalling in stem cells and cancer
T Reya et al.
NATURE (2005)
ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma
R Grützmann et al.
BRITISH JOURNAL OF CANCER (2004)
Epithelial-cadherin and β-catenin expression changes in pancreatic intraepithelial neoplasia
MM Al-Aynati et al.
CLINICAL CANCER RESEARCH (2004)
ADAM8 as a novel serological and histochemical marker for lung cancer
N Ishikawa et al.
CLINICAL CANCER RESEARCH (2004)
Minireview:: GNAS:: Normal and abnormal functions
LS Weinstein et al.
ENDOCRINOLOGY (2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells
T Asano et al.
ONCOGENE (2004)
PI3K-Akt pathway: Its functions and alterations in human cancer
M Osaki et al.
APOPTOSIS (2004)
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
AJ Aguirre et al.
GENES & DEVELOPMENT (2003)
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
SP Thayer et al.
NATURE (2003)
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
MJ Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity
B Wang et al.
CANCER CELL (2003)
Notch mediates TGFα-induced changes in epithelial differentiation during pancreatic tumorigenesis
Y Miyamoto et al.
CANCER CELL (2003)
ATM and related protein kinases: Safeguarding genome integrity
Y Shiloh
NATURE REVIEWS CANCER (2003)
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
CJ Bakkenist et al.
NATURE (2003)
DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma
AV Biankin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
SR Bramhall et al.
BRITISH JOURNAL OF CANCER (2002)
Death and anti-death: Tumour resistance to apoptosis
FH Igney et al.
NATURE REVIEWS CANCER (2002)
MLL3, a new human member of the TRX/MLL gene family, maps to 7q36, a chromosome region frequently deleted in myeloid leukaemia
M Ruault et al.
GENE (2002)
Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis:: dissection of Ras signaling pathways
E Janda et al.
JOURNAL OF CELL BIOLOGY (2002)
Mammalian G1- and S-phase checkpoints in response to DNA damage
J Bartek et al.
CURRENT OPINION IN CELL BIOLOGY (2001)
Relative frequency and morphology of cancers in carriers of germline TP53 mutations
JM Birch et al.
ONCOGENE (2001)
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
J Falck et al.
NATURE (2001)
DNA damage-induced activation of p53 by the checkpoint kinase Chk2
A Hirao et al.
SCIENCE (2000)
BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia -: Evidence and implications
M Goggins et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
